Sequential almonertinib therapy following osimertinib-induced interstitial lung disease in early-stage EGFR-mutant lung adenocarcinoma: a case report

Background Osimertinib is the standard adjuvant therapy for resected epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). However, its use is limited by osimertinib-induced interstitial lung disease (Osi-ILD). Case Presentation We describe the case of a 62-year-old woman with resected stage IIB (pT1cN1M0) EGFR L858R-mutant lung adenocarcinoma who developed grade 2 Osi-ILD, characterized by new bilateral ground-glass opacities on high-resolution computed tomography (